PEER-REVIEW REPORT

Name of journal: World Journal of Hematology
Manuscript NO: 71725
Title: Efficacy of H 30-II column hemoadsorption in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis combined with liver failure: A case report
Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 05412313
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer’s Country/Territory: Morocco
Author’s Country/Territory: China
Manuscript submission date: 2021-09-29
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-09-29 15:16
Reviewer performed review: 2021-10-04 17:57
Review time: 5 Days and 2 Hours

Scientific quality

[ ] Grade A: Excellent  [ ] Grade B: Very good  [ Y] Grade C: Good
[ ] Grade D: Fair  [ ] Grade E: Do not publish

Language quality

[ ] Grade A: Priority publishing  [ Y] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing  [ ] Grade D: Rejection

Conclusion

[ ] Accept (High priority)  [ ] Accept (General priority)
[ Y] Minor revision  [ ] Major revision  [ ] Rejection

Re-review

[ Y] Yes  [ ] No
SPECIFIC COMMENTS TO AUTHORS
- history of past illness and personnel and familial past history must be putted before history of present illness - how many days before her admission, the little girl have fever
- line 135: one day 1 ? what that it mean? - author should explain more chemotherapy protocol HLH-2004 (drugs) - does patient present any side effects of chemotherapy
Name of journal: *World Journal of Hematology*

Manuscript NO: 71725

**Title:** Efficacy of H-30-II column hemoadsorption in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis combined with liver failure: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 05219083

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Doctor, Professor, Surgeon

**Reviewer’s Country/Territory:** Mexico

**Author’s Country/Territory:** China

**Manuscript submission date:** 2021-09-29

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-10-06 18:15

**Reviewer performed review:** 2021-10-12 16:55

**Review time:** 5 Days and 22 Hours

### Scientific quality

- [ ] Grade A: Excellent
- [ ] Grade B: Very good
- [Y] Grade C: Good
- [ ] Grade D: Fair
- [ ] Grade E: Do not publish

### Language quality

- [ ] Grade A: Priority publishing
- [Y] Grade B: Minor language polishing
- [ ] Grade C: A great deal of language polishing
- [ ] Grade D: Rejection

### Conclusion

- [ ] Accept (High priority)
- [ ] Accept (General priority)
- [Y] Minor revision
- [ ] Major revision
- [ ] Rejection

### Re-review

- [ ] Yes
- [Y] No
SPECIFIC COMMENTS TO AUTHORS
Comments and suggestions for the authors. 1 Title. Does the title reflect the main subject/hypothesis of the manuscript? ANSWER: Yes 2 Abstract. Does the abstract summarize and reflect the work described in the manuscript? ANSWER: Yes 3 Key words. Do the key words reflect the focus of the manuscript? ANSWER: Yes 4 Background. Does the manuscript adequately describe the background, present status and significance of the study? ANSWER: Yes 5 Methods. Does the manuscript describe methods (e.g., experiments, data analysis, surveys, and clinical trials, etc.) in adequate detail? ANSWER: These aspects do not apply. 6 Results. Are the research objectives achieved by the experiments used in this study? ANSWER: This does not apply. What are the contributions that the study has made for research progress in this field? ANSWER: The use of the HA330-II column hemoadsorption therapeutic option in hemophagocytic lymphohistiocytosis associated with the Epstein-Barr virus combined with liver failure. 7 Discussion. Does the manuscript interpret the findings adequately and appropriately, highlighting the key points concisely, clearly and logically? ANSWER: Yes Are the findings and their applicability/relevance to the literature stated in a clear and definite manner? ANSWER: The use of the HA330-II column hemaadsorption therapeutic option in hemophagocytic lymphohistiocytosis associated with the Epstein-Barr virus combined with liver failure should be evaluated on a larger scale, with randomized controlled studies to really determine its efficacy, and not just a clinical case. Is the discussion accurate and does it discuss the paper’s scientific significance and/or relevance to clinical practice sufficiently? ANSWER: Yes, but in a very limited way. 8 Illustrations and tables. Are the figures, diagrams and tables
sufficient, good quality and appropriately illustrative of the paper contents? ANSWER: The 2 figures presented by the authors are low resolution due to their small size. I suggest presenting them in 300% to 400% larger size. Do figures require labeling with arrows, asterisks etc., better legends? ANSWER: No. 9 Biostatistics. Does the manuscript meet the requirements of biostatistics? ANSWER: This does not apply. 10 Units. Does the manuscript meet the requirements of use of SI units? ANSWER: Yes. 11 References. Does the manuscript cite appropriately the latest, important and authoritative references in the introduction and discussion sections? ANSWER: Yes. Only Reference 7 needs to be worded correctly, there are some errors. Does the author self-cite, omit, incorrectly cite and/or over-cite references? ANSWER: No 12 Quality of manuscript organization and presentation. Is the manuscript well, concisely and coherently organized and presented? ANSWER: Yes Is the style, language and grammar accurate and appropriate? ANSWER: Yes. 13 Research methods and reporting. Authors should have prepared their manuscripts according to manuscript type and the appropriate categories, as follows: (1) CARE Checklist (2013) - Case report; (2) CONSORT 2010 Statement - Clinical Trials study, Prospective study, Randomized Controlled trial, Randomized Clinical trial; (3) PRISMA 2009 Checklist - Evidence-Based Medicine, Systematic review, Meta-Analysis; (4) STROBE Statement - Case Control study, Observational study, Retrospective Cohort study; and (5) The ARRIVE Guidelines - Basic study. Did the author prepare the manuscript according to the appropriate research methods and reporting? ANSWER: Yes 14 Ethics statements. For all manuscripts involving human studies and/or animal experiments, author(s) must submit the related formal ethics documents that were reviewed and approved by their local ethical review committee. Did the manuscript meet the requirements of ethics? ANSWER: Yes. Specific Comments To Authors: Please make your specific comments/suggestions to authors based on the above-listed criteria checklist for new
manuscript peer-review and the below-listed criteria for comments on writing. The criteria for writing comments include the following three features: First, what are the original findings of this manuscript? ANSWER: Probable positive therapeutic response in the patient in relation to improving the intense inflammatory response of the patient and providing support while improving liver function. What are the new hypotheses that this study proposed? ANSWER: Hemoadsorption may play an important role in eliminating cytokines storm in children with Hemophagocytic lymphohistiocytosis combined with liver failure and consequent multiple organ failure. What are the new phenomena that were found through experiments in this study? ANSWER: This does not apply. What are the hypotheses that were confirmed through experiments in this study? ANSWER: This does not apply. Second, what are the quality and importance of this manuscript? ANSWER: The use of the HA330-II column hemaadsorption therapeutic option in hemophagocytic lymphohistiocytosis associated with the Epstein-Barr virus combined with liver failure. What are the new findings of this study? ANSWER: Probable positive therapeutic response in the patient in relation to improving the intense inflammatory response of the patient and providing support while improving liver function. What are the new concepts that this study proposes? ANSWER: The use of the HA330-II column hemaadsorption therapeutic option in hemophagocytic lymphohistiocytosis associated with the Epstein-Barr virus combined with liver failure. What are the new methods that this study proposed? ANSWER: None. Do the conclusions appropriately summarize the data that this study provided? ANSWER: Yes. What are the unique insights that this study presented? ANSWER: The use of the HA330-II column hemaadsorption therapeutic option in hemophagocytic lymphohistiocytosis associated with the Epstein-Barr virus combined with liver failure. What are the key problems in this field that this study has solved? ANSWER: yes. Third, what are the limitations of the study and its findings? ANSWER: The main one
is that it is a clinical case report. What are the future directions of the topic described in this manuscript? ANSWER: the therapeutic method must be evaluated on a larger scale, with randomized controlled studies to really determine its efficacy, and not just a clinical case. What are the questions/issues that remain to be solved? ANSWER: The true utility and efficacy of the therapeutic method used in this clinical case. What are the questions that this study prompts for the authors to do next? ANSWER: What is the true efficacy of the therapeutic method used? How might this publication impact basic science and/or clinical practice? ANSWER: In clinical practice, you can motivate further studies by applying this treatment option.